Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis

Rituximab (RTX) may benefit patients with glomerular disease who suffer from focal segmental glomerular sclerosis (FSGS) or minimal change disease (MCD). Here, we have described our experience treating 6 FSGS and 9 MCD patients with steroid-dependent/refractory nephrotic syndrome (NS) with RTX. Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Hong, Lin, Li, Shen, Pingyan, Li, Xiao, Xie, Jingyuan, Pan, Xiaoxia, Zhang, Wen, Chen, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper: Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706808/
https://www.ncbi.nlm.nih.gov/pubmed/29212162
http://dx.doi.org/10.18632/oncotarget.21833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706808/
https://www.ncbi.nlm.nih.gov/pubmed/29212162
http://dx.doi.org/10.18632/oncotarget.21833

Ejemplares similares